2m 2m 2m 2m 2m 2m 2m
Dr Reddy's Lb SpADR (RDY)
NYSE
$14.32+$0.41 (+2.95%)
Price as of Jun 23, 2026 6:24 PM EDT- $11.6BMarket Cap
- -8.58%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Dr Reddy's Lb SpADR (RDY)
$14.32+$0.41 (+2.95%)
Annual
Quarterly
03/31/2026 | 03/31/2025 | 03/31/2024 | 03/31/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.6B -6.06% | 3.8B +13.76% | 3.4B +11.97% | 3.0B +5.87% | |
Cost of Revenue | 1.7B +6.96% | 1.6B +13.99% | 1.4B +7.02% | 1.3B -2.19% | |
Gross Profit | 1.9B -15.29% | 2.2B +13.60% | 2.0B +15.81% | 1.7B +13.00% | |
Sales and Marketing Expense | 1.1B +3.46% | 1.1B +18.68% | 926.0M +11.84% | 828.0M +1.22% | |
Research and Development Expense | -256.0M -20.00% | -320.0M +16.79% | -274.0M +16.10% | -236.0M +2.61% | |
Depreciation and Amortization Expense | 220.0M +10.00% | 200.0M +12.36% | 178.0M +15.58% | 154.0M -1.28% | |
Total Operating Expenses | 1.1B +3.46% | 1.1B +18.68% | 926.0M +11.84% | 828.0M +1.22% | |
Operating Profit | 539.0M -35.99% | 842.0M +3.57% | 813.0M +16.98% | 695.0M +78.66% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -3.7B +32.13% | -2.8B +65.34% | -1.7B +19.82% | -1.4B +49.06% | |
Interest Income and Expense and Net | -3.7B +32.13% | -2.8B +65.34% | -1.7B +19.82% | -1.4B +49.06% | |
Total Nonoperating Income and Expense | 3.7B +32.13% | 2.8B +65.34% | 1.7B +19.82% | 1.4B +49.06% | |
Income before Taxes | 452.0M -32.64% | 671.0M +0.45% | 668.0M +21.90% | 548.0M +76.21% | |
Income Taxes | 132.0M -42.36% | 229.0M +18.04% | 194.0M +4.30% | 186.0M +61.74% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 452.0M -32.64% | 671.0M +0.45% | 668.0M +21.90% | 548.0M +76.21% | |
Net Income from Continuing Operations Applicable to Common | 452.0M -32.64% | 671.0M +0.45% | 668.0M +21.90% | 548.0M +76.21% | |
Basic EPS and Net Income | 0.55 -30.38% | 0.79 -80.35% | 4.02 +21.82% | 3.30 +76.47% | |
Diluted EPS and Net Income | 0.55 -30.38% | 0.79 -80.30% | 4.01 +21.52% | 3.30 +76.47% | |
Basic Weighted Average Shares | 832.4M -0.06% | 833.0M +400.59% | 166.4M +0.22% | 166.0M +0.09% | |
Diluted Weighted Average Shares | 832.4M -0.06% | 833.0M +400.59% | 166.4M +0.22% | 166.0M +0.09% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 164.0M -4.65% | 172.0M +102.35% | 85.0M +21.43% | 70.0M -64.29% | |
Short-Term Investments | 772.0M +52.57% | 506.0M -43.27% | 892.0M +30.79% | 682.0M +75.32% | |
Cash and Cash Equivalents and Short-Term Investments | 936.0M +38.05% | 678.0M -30.60% | 977.0M +29.92% | 752.0M +28.55% | |
Total Current Assets | 3.2B +9.94% | 2.9B -1.61% | 3.0B +18.19% | 2.5B +5.05% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 1.2B +8.04% | 1.1B +23.94% | 923.0M +14.09% | 809.0M -1.22% | |
Total Long-Term Assets | 3.0B +3.94% | 2.8B +69.99% | 1.7B +19.67% | 1.4B -4.44% | |
Total Assets | 6.2B +6.98% | 5.8B +24.13% | 4.7B +18.74% | 3.9B +1.45% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 630.0M +41.57% | 445.0M +190.85% | 153.0M +70.00% | 90.0M -74.79% | |
Total Current Liabilities | 1.8B +17.03% | 1.5B +32.55% | 1.2B +10.34% | 1.0B -15.74% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 334.0M +12.08% | 298.0M +125.76% | 132.0M +116.39% | 61.0M -44.04% | |
Total Liabilities | 2.1B +16.22% | 1.8B +42.13% | 1.3B +16.09% | 1.1B -17.95% | |
Retained Earnings | 3.8B +1.46% | 3.7B +16.15% | 3.2B +21.35% | 2.6B +13.26% | |
Total Stockholders Equity | 4.1B +2.71% | 3.9B +17.26% | 3.4B +19.79% | 2.8B +11.91% | |
Total Shares Outstanding | 832.0M -0.08% | 832.6M +401.12% | 166.2M +0.12% | 166.0M +0.14% | |
Cash Flow | |||||
Cash from Operating Activities | 607.0M +11.38% | 545.0M 0.00% | 545.0M -23.88% | 716.0M +93.51% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -700.0M +2.64% | -682.0M +41.20% | -483.0M -3.98% | -503.0M +44.54% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 88.0M -60.36% | 222.0M +593.33% | -45.0M -86.24% | -327.0M +921.88% | |
Financials Ratio | |||||
Gross Margin | 52.77% -9.83% | 58.51% -0.14% | 58.60% +3.37% | 56.68% +6.72% | |
Operating Margin | 15.06% -31.85% | 22.09% -8.96% | 24.27% +4.48% | 23.23% +68.75% | |
Return on Assets | 7.57% -41.24% | 12.88% -17.44% | 15.60% +10.66% | 14.09% +69.73% | |
Return on Equity | 11.30% -38.43% | 18.35% -15.17% | 21.63% +5.02% | 20.60% +61.50% | |
Revenue Growth | -6.06% -144.05% | 13.76% +15.01% | 11.97% +103.70% | 5.87% +105.96% | |
Current Ratio | 1.80 -6.06% | 1.92 -25.77% | 2.58 +7.11% | 2.41 +24.67% | |
Cash Ratio | 0.09 -18.47% | 0.11 +52.57% | 0.07 +10.15% | 0.07 -57.65% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow